A Study of Linperlisib Combination With Camrelizumab in Patients With Solid Tumor
Clinical trial NCT05429398 · UNKNOWN
Trial details
- NCT number
- NCT05429398
- Sponsor
- Shanghai YingLi Pharmaceutical Co. Ltd.
- Status
- UNKNOWN
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2022-06-30
- Primary completion
- 2023-08-31
- Enrollment
- 118
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.